Congratulations to Work Package 7 working group for publishing some of the work carried out as part of SOPHIA. The research highlights the lived experiences of people living with obesity during the COVID-19 pandemic. It highlights the challenge sustaining treatment and psychosocial impact during these unprecedented times.
The research article was published on the 4th of Sep in Clinical Obesity, click here for full access.
The project is funded by a grant from the Innovative Medicines Initiative (IMI) – a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA); JDRF (formerly the Juvenile Diabetes Research Foundation); the Obesity Action Coalition; and T1D Exchange.
About IMI
The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). For further information: www.imi.europa.eu
